Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by Gotham Asset Management LLC

Gotham Asset Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 199,127 shares of the company's stock after selling 18,510 shares during the quarter. Johnson & Johnson makes up about 0.3% of Gotham Asset Management LLC's portfolio, making the stock its 25th biggest holding. Gotham Asset Management LLC's holdings in Johnson & Johnson were worth $28,798,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $32,000. Finally, Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Finally, Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

JNJ traded down $0.34 during midday trading on Monday, reaching $153.88. 9,022,599 shares of the company's stock were exchanged, compared to its average volume of 7,904,724. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business's 50-day moving average price is $157.89 and its 200 day moving average price is $154.23. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock has a market capitalization of $370.24 billion, a PE ratio of 23.14, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.